Adeleh Divsalar

Dr. Adeleh Divsalar

Kharazmi University, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2016 in Journal of the Iranian Chemical Society
Verified
Journal Article
Closed access
PDF file
EJEhsan Zareian Jahromi
Ehsan Zareian Jahromi
ADAdeleh Divsalar
Adeleh Divsalar
ASAli Akbar Saboury
Ali Akbar Saboury
SKSara Khaleghizadeh
Sara Khaleghizadeh
HMHassan Mansouri-Torshizi
Hassan Mansouri-Torshizi
Irena KostovaIrena Kostova
Irena Kostova

1 July 2017 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
ZSZahra Shafaei
Zahra Shafaei
BGBehafarid Ghalandari
Behafarid Ghalandari
AVAkbar Vaseghi
Akbar Vaseghi
ADAdeleh Divsalar
Adeleh Divsalar
THThomas Haertlé
Thomas Haertlé
LSLindsay Sawyer
Lindsay Sawyer

29 October 2014 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
BGBehafarid Ghalandari
Behafarid Ghalandari
ADAdeleh Divsalar
Adeleh Divsalar
MEMahbube Eslami-Moghadam
Mahbube Eslami-Moghadam
ASAli Akbar Saboury
Ali Akbar Saboury
THThomas Haertlé
Thomas Haertlé
KPKazem Parivar
Kazem Parivar

24 March 2016 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
ZIZhila Izadi
Zhila Izadi
ADAdeleh Divsalar
Adeleh Divsalar
ASAli Akbar Saboury
Ali Akbar Saboury
LSLindsay Sawyer
Lindsay Sawyer

3 March 2023 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
STSarvenaz Moradi Taklimi
Sarvenaz Moradi Taklimi
ADAdeleh Divsalar
Adeleh Divsalar
BGBehafarid Ghalandari
Behafarid Ghalandari
XDXianting Ding
Xianting Ding
Maria Luisa Di GioiaMaria Luisa Di Gioia
Maria Luisa Di Gioia
ASAli Akbar Saboury
Ali Akbar Saboury

14 January 2015 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
MMM. Moradi
M. Moradi
ADAdeleh Divsalar
Adeleh Divsalar
ASA.A. Saboury
A.A. Saboury
BGBehafarid Ghalandari
Behafarid Ghalandari
AHA.R. Harifi
A.R. Harifi
Deferasirox (DFX), as an oral chelator, is used for treatment of transfusional iron overload. In this study, we have investigated the effects of DFX as an iron chelator, on the function and structure of bovine liver catalase (BLC) by different spectroscopic methods of UV–visible, fluorescence, and circular dichroism (CD) at two temperatures of 25 and 37 °C. In vitro kinetic studies showed that DFX can inhibit the enzymatic activity in a competitive manner. K I value was calculated 39 nM according to the Lineweaver–Burk plot indicating a high rate of inhibition of the enzyme. Intrinsic fluorescence data showed that increasing the drug concentrations leads to a significant decrease in the intrinsic emission of the enzyme indicating a significant change in the three-dimensional environment around the chromophores of the enzyme structure. By analyzing the fluorescence quenching data, it was found that the BLC has two binding sites for DFX and the values of binding constant at 25 and 37 °C were calculated 1.7 × 107 and 3 × 107 M−1, respectively. The static type of quenching mechanism is involved in the quenching of intrinsic emission of enzyme. The thermodynamic data suggest that hydrophobic interactions play a major role in the binding reaction. UV–vis spectroscopy results represented the changes in tryptophan (Trp) absorption and Soret band spectra, which indicated changes in Trp and heme group position caused by the drug binding. Also, CD data represented that high concentrations of DFX lead to a significant decreasing in the content of β-sheet and random coil accompanied an increasing in α-helical content of the protein. The molecular docking results indicate that docking may be an appropriate method for prediction and confirmation of experimental results and also useful for determining the binding mechanism of proteins and drugs. According to above results, it can be concluded that the DFX can chelate the Fe(III) on the enzyme active site leading to changes in the function and structure of catalase which can be considered as a side effect of this drug and consequently has an important role in hepatic complications and fibrosis.